Markets:

Overview

News

Currencies

International

Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

32.25 +1.25 (+4.03%)

Streaming Delayed Price Updated: 11:30 AM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

31 32 Next >

What Does the Market Think About Teva Pharmaceutical Indus? ↗

April 30, 2025

Via Benzinga

Trump Tariff Sell-Off: 3 Superb Stocks That Make for No-Brainer Buys Right Now ↗

April 21, 2025

Short-term uncertainty has led to a golden opportunity for long-term investors.

Via The Motley Fool

5 of the Safest Stocks Billionaire Money Managers Bought Ahead of Wall Street's Historic Volatility ↗

April 13, 2025

Some of Wall Street's most-prominent asset managers were scooping up shares of time-tested businesses before the stock market meltdown.

Via The Motley Fool

Topics Government Stocks World Trade

Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports ↗

April 09, 2025

Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports.

Via Investor's Business Daily

Topics Government Stocks World Trade

Forecasting The Future: 6 Analyst Projections For Teva Pharmaceutical Indus ↗

March 06, 2025

Via Benzinga

Spotlight on Teva Pharmaceutical Indus: Analyzing the Surge in Options Activity ↗

February 10, 2025

Via Benzinga

Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States

April 07, 2025

From Teva Pharmaceutical Industries Ltd; Samsung Bioepis Co., Ltd.

Via GlobeNewswire

Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention

April 07, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

New Data Strengthens Teva’s Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable

March 31, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

These Are My 3 Worst-Performing Stocks So Far in 2025 -- and the One I'm Buying More of Now ↗

March 28, 2025

Via The Motley Fool

Teva Releases Q1 2025 Aide Memoire

March 27, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025

March 27, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Billionaire Stanley Druckenmiller Jettisoned Shares of Palantir and Nvidia, and Is Piling Into 3 High-Profile Turnaround Stocks ↗

March 24, 2025

Duquesne Family Office's chief is dumping shares of Wall Street's hottest artificial intelligence (AI) stocks in favor of a trio of companies that are righting their respective ships.

Via The Motley Fool

Topics Artificial Intelligence

Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings ↗

March 19, 2025

Via The Motley Fool

Is SoundHound AI Stock a Buy Now? ↗

March 05, 2025

Via The Motley Fool

Topics Artificial Intelligence

Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in March

March 03, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva Pharmaceuticals

February 27, 2025

The $2 million in new funding is part of a $4 million commitment from Teva, launched in 2022, to expand access to critical mental health services across 10 states

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I Disorder

February 25, 2025

From Teva Pharmaceutical Industries Ltd; Medincell

Via GlobeNewswire

Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease ↗

February 24, 2025

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with plans for a Phase 3 trial in 2025.

Via Benzinga

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

February 22, 2025

Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Teva and Alvotech Announce SELARSDI™ (ustekinumab-aekn) Injection Now Available in the U.S.

February 21, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Billionaire Stanley Druckenmiller Dumped Duquesne's Entire Stake in Broadcom and Bought One of Wall Street's Hottest Drug Stocks Hand Over Fist ↗

February 20, 2025

Duquesne Family Office's billionaire chief shed a trillion-dollar artificial intelligence (AI) stock in favor of a historically cheap drugmaker that's more than doubled in less than two years.

Via The Motley Fool

Topics Artificial Intelligence

Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)

February 18, 2025

From Teva Pharmaceutical Industries Ltd

Via GlobeNewswire

Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

February 18, 2025

From Teva Pharmaceutical Industries Ltd; Alvotech

Via GlobeNewswire

Billionaire Investor Stanley Druckenmiller Dumps Broadcom, Bets Big On Tesla, Amazon And Other Big Tech Stocks In Q4 ↗

February 18, 2025

Billionaire investor Stanley Druckenmiller's family office Duquesne has divested his entire stake in Broadcom, simultaneously increasing his investments in major tech companies, as revealed in a recent...

Via Benzinga

WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio? ↗

February 16, 2025

Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%)

Via Benzinga

This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy? ↗

February 16, 2025

Via The Motley Fool

Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025' ↗

February 10, 2025

Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.

Via Benzinga

Topics Intellectual Property

MarketBeat Week in Review – 02/03 - 02/07

February 08, 2025

Despite a Monday sell-off, stocks ended the week higher, and there's evidence that sector rotation is underway; next week's read of inflation may move markets.

Via MarketBeat

Topics Artificial Intelligence Economy World Trade

Neurocrine Biosciences Reports Mixed Q4 ↗

February 07, 2025

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while revenue slightly missed estimates.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

31 32 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.